Nippon Venture Capital backs Chordia Therapeutics IPO

Health Care · Japan · Undisclosed

Nippon Venture Capital (NVCC) was an early institutional backer of Chordia Therapeutics, a Fujisawa-based oncology biotech, ahead of its June 14, 2024 listing on the Tokyo Stock Exchange Growth Market -- one of 160+ IPO exits in NVCC's portfolio history. Specific committed amount undisclosed.